Trial · NCT06736691
Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections
NCT06736691, Phase 3, Completed, Swiss Tropical & Public Health Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections. Trials, record NCT06736691. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06736691
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections
- NCT number
- NCT06736691
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 315 participants, actual
- Lead sponsor
- Swiss Tropical & Public Health Institute
- Conditions
- Trichuris Trichiura; Infection, Hookworm Infection, Ascaris Lumbricoides Infection
- Interventions
- emodepside (BAY 44-4400), matching placebo of emodepside, Mebendazole, similar placebo to mebendazole
- First posted
- 2024-12-17
- Last updated
- 2026-10-08
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cured of T. trichiura infection | Test of Cure Visit at 14 to 21 days after end of treatment | Determined by negative Kato-Katz thick smears in two stool samples taken at the Test of Cure Visit |
| Secondary | Cured of A. lumbricoides infection | Test of Cure Visit at 14 to 21 days after end of treatment | Determined by negative Kato-Katz thick smears in two stool samples taken at the Test of Cure Visit. This endpoint is only applicable for the subgroup of participants co-infected with A. lumbricoides at baseline. |
| Secondary | Occurrence of TEAEs | Adverse events that occur after the first dose of study intervention up to 21 days after the last dose of study intervention | Defined as any AE that occurred or worsened after the first dose of study intervention up to 21 days after the last dose of study intervention |
| Other | Cured of hookworm infection | Test of Cure Visit at 14 to 21 days after end of treatment | Determined by negative Kato-Katz thick smears in two stool samples taken at the Test of Cure Visit. This endpoint is only applicable for the subgroup of participants co-infected with hookworm at baseline. |
| Other | Egg reduction of each species of STH (T. trichiura, A. lumbricoides and hookworm infection) | Test of Cure Visit at 14 to 21 days after end of treatment | Defined as logarithm of the number of eggs/g (+1) from stool samples taken at the Test of Cure Visit minus the logarithm of the number of eggs/g (+1) in stool samples taken at baseline. Egg reduction of A. lumbricoides and hookworm will only be calculated in participants co-infected with A. lumbricoides and hookworm at baseline, respectively. |
| Other | Listing of individual plasma concentrations of emodepside | Plasma concentrations at 3, 6, 21-48 hours and 14-21 days after the end of treatment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06736691
GET https://conductscience.org/api/trials/v1/NCT06736691/registered